

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application.

1. (Previously presented) A tablet for use in a drip tray, the tablet including:

an excipient selected so that the tablet will not fully dissolve in water at ambient temperature for a period of at least three months;
at least 500 ppm of a biocide;
at least one enzyme; and
enzyme preserving means for maintaining enzyme activity in a moist environment.
2. (Original) A tablet according to claim 1 wherein the excipient is selected such that the tablet will not fully dissolve in water at ambient temperature for a period of at least 6 months.
3. (Original) A tablet according to claim 1 wherein the excipient is selected such that the tablet will not fully dissolve in water at ambient temperature for a period of at least 12 months.
4. (Previously presented) A tablet according to claim 1 wherein the excipient includes one or more compounds selected from the group consisting of poly vinyl alcohols, high molecular weight polyethylene glycols, high molecular weight polypropylene glycols, esters or partial esters of polyethylene glycols or of polypropylene glycols, and high molecular weight thermoplastic surfactants.
5. (Currently amended) A tablet according to claim 4 wherein the excipient includes one or more high molecular weight thermoplastic surfactants ~~compounds~~ selected from the group consisting of polyoxyethylene condensates, polyoxypropylene condensates, polyoxyethylene-polyoxypropylene copolymers with appropriate hydrophobes, and combinations thereof.
6. (Previously presented) A tablet according to claim 1 wherein the at least one enzyme is selected from the group consisting of proteolytic and hydrolase enzymes.
7. (Previously presented) A tablet according to claim 1 wherein the enzyme preserving means includes a boron compound.

8. (Original) A tablet according to claim 7 wherein the boron compound is present in a concentration sufficient to maintain enzyme activity for at least three months during use.
9. (Previously presented) A tablet according to claim 1 wherein the excipient comprises 2% to 95% by weight of the tablet.
10. (Previously presented) A tablet according to claim 9 wherein the excipient comprises 10% to 80% by weight of the tablet.
11. (Previously presented) A tablet according to claim 10 wherein the excipient comprises 20% to 60% by weight of the tablet.
12. (Previously presented) A tablet according to claim 1 wherein the at least one enzyme comprises up to 20% by weight of the tablet.
13. (Previously presented) A tablet according to claim 12 wherein the at least one enzyme comprises up to 10% by weight of the tablet
14. (Previously presented) A tablet according to claim 13 wherein the at least one enzyme comprises up to 5% by weight of the tablet.
15. (Previously presented) A tablet according to claim 14 wherein the at least one enzyme comprises up to 3% by weight of the tablet.
16. (Previously presented) A tablet according to claim 1 wherein the enzyme preserving means is present in an amount of from 0.1% to 10% by weight of the tablet.
17. (Previously presented) A tablet according to claim 16 wherein the enzyme preserving means is present in an amount of from 0.1% to 3% by weight of the tablet.
18. (Previously presented) A tablet according to claim 1 wherein the biocide is present in an amount of from 0.1% to 20% by weight of the tablet.
19. (Previously presented) A tablet according to claim 18 wherein the biocide is present in an amount of from 0.5% to 10% by weight of the tablet.
20. (Previously presented) A tablet according to claim 19 wherein the biocide is present in an amount of from 1% to 5% by weight of the tablet.

21. (Previously presented) A tablet according to claim 1 further including a surfactant.
22. (Previously presented) A tablet according to claim 1 when made in a tablet press.
23. (Previously presented) A tablet according to claim 1 when made by a process including the step of moulding.
24. (Previously presented) A tablet according to claim 1 when made by a process including the step of extrusion.
25. (Currently amended) A tablet according to claim 1 ~~when provided with that is a~~ slow release encapsulated~~ion~~ tablet.
26. (Previously presented) A method for inhibiting the growth of a biofilm in a drip tray or the like, including the step of adding to the tray, a tablet including:

an excipient selected so that the tablet will not fully dissolve in water at ambient temperature
for a period of at least three months;
at least 500 ppm of a biocide;
at least one enzyme; and
enzyme preserving means for maintaining enzyme activity in a moist environment.

27–28. (Canceled)